Document Detail

Vorapaxar: First Global Approval.
MedLine Citation:
PMID:  24962425     Owner:  NLM     Status:  Publisher    
Vorapaxar [Zontivity(®) (US)], an orally active protease-activated receptor-1 (PAR-1) receptor antagonist, has been developed by Merck & Co for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). Vorapaxar has received its first global approval for this indication in the US. This article summarizes the milestones in the development of vorapaxar leading to this first approval for the reduction of thrombotic cardiovascular events in patients with a prior MI or PAD.
Raewyn M Poole; Shelley Elkinson
Related Documents :
9784925 - Effect and mechanism of cardioplegic arrest on the coronary endothelium-smooth muscle i...
1405675 - Effect of an oxygen-enriched solution and multiple dosing of antegrade crystalloid card...
21856225 - Left-ventricular non-compaction with congenital left ventricular diverticulum.
926815 - Cold cardioplegia or continuous coronary perfusion? report on preliminary clinical expe...
1512345 - Ventricular tachycardia after surgical repair of tetralogy of fallot: results of intrao...
3396175 - Failure of epinephrine to improve the balance between myocardial oxygen supply and dema...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-6-25
Journal Detail:
Title:  Drugs     Volume:  -     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-6-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evolution of Drug Resistance in Tuberculosis: Recent Progress and Implications for Diagnosis and The...
Next Document:  Perceptions of melanoma risk among Australian adolescents: barriers to sun protection and recommenda...